**Fibrinogen Concentrate** *(Fibryga)*

**Indication(s):** Remote Damage Control
Resuscitation (Treatment of acute bleeding episodes).

**Contraindications:** Hypersensitivity to Fibryga or its components.

**Precautions:** Weigh the benefits of Fibryga administration versus the risk of thrombosis. Patients receiving Fibryga should be monitored for signs and symptoms of thrombosis. Safety has not been determined in pregnancy and nursing (Weigh Risk vs Benefit).

**Drug Interactions:** Fibryga should not be directly mixed with other medicinal products.

**Pharmacology:** Fibrinogen (factor I) is a soluble plasma protein that, during the coagulation process, is converted to fibrin, one of the key components of the blood clot. It is disproportionately susceptible to depletion during trauma, therefore, supplementation aims to restore normal coagulation activation.

**Adverse Effects:** No serious adverse reactions have been reported in clinical studies with Fibryga so far. The most serious adverse reactions that may potentially be observed include thromboembolic episodes and anaphylactic type reactions.

**Dosage and Administration:** If fluid resuscitation therapy is warranted, administer 4g Fibryga IV/IO as soon as practical. Refer to product insert for reconstitution directions.